Results 111 to 120 of about 185,906 (291)

Differential Diagnosis for Nail Psoriasis

, 2014
Nail involvement occurs in up to 50 % of patients with psoriasis. Although most patients experience concurrent skin involvement, 1–5 % of patients present with nail changes alone. In these patients, it can be diagnostically challenging, as psoriatic nail
Antonella Tosti, Yin, Natalie C, Natalie C. Yin, Tosti, Antonella   +3 more
core   +1 more source

Deep Immunophenotyping Reveals Distinct Immune Signatures in Axial Spondyloarthritis and Psoriatic Arthritis

Arthritis &Rheumatology, EarlyView.
Objective Axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) are overlapping yet distinct conditions within the SpA spectrum. As divergent immunophenotypes may influence disease course and therapeutic response, we compared immune cell subsets, cytokine profiles, and inflammatory mediators.
Natalie Frede, Nils Craig‐Müller, Silke Kohrt, Marei‐Theresa Bott, Ulrich Salzer, Ana Cecilia Venhoff, Jens Thiel, Julia Frede, Reinhard E. Voll, Marta Rizzi, Raquel Lorenzetti, Nils Venhoff   +11 more
wiley   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, Accepted Article.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week (W), double‐blind, placebo‐controlled, phase 3 POETYK PsA‐2 study
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source

Risk of Cancer According to Duration of Targeted Therapy Exposure in Spondyloarthritis: A Nationwide Cohort Study From the French Health Insurance Database

Arthritis &Rheumatology, EarlyView.
Objective To assess the association between duration of targeted therapy exposure and cancer risk in patients with spondyloarthritis (SpA), including those with psoriatic arthritis, axial SpA, and other subtypes. Methods This nationwide cohort study used the French health insurance database to identify adults with SpA initiating a targeted therapy ...
Karine Tankovic, Pascal Claudepierre, Tat Thang Vo, Tran Trong Khoi Le, Siham Iggui, Laetitia Penso, Emilie Sbidian, Laura Pina Vegas   +7 more
wiley   +1 more source

“Psoriasis, factor de riesgo para desarrollar enfermedades cardiovasculares y síndrome metabólico”

, 2017
La psoriasis es una enfermedad crónica inflamatoria común que se caracteriza por la presencia de placas eritematosas de bordes definidos con placas plateadas. Tiene un carácter multifactorial y se relaciona con varias enfermedades.
Ponce Torres, Christian David
core   +1 more source

COVID-19 in patients with psoriasis: A Latin American case series

JAAD International, 2021
Isabela Campo-Slebi, MD, María Fernanda Meza-Corso, MD, Paola Cárdenas, MD, Juan Raúl Castro-Ayarza, MD, Cesar González, MD, Carolina Cortés, MD, Manuel Franco, MD, Fernando Valenzuela, MD   +7 more
doaj   +1 more source

Impact of Dual Interleukin‐17A and Interleukin‐17F Inhibition with Bimekizumab on Inflammatory and Structural Lesions in Axial Spondyloarthritis: MRI and Radiographic Outcomes from the Phase 3 BE MOBILE 1 and 2 Studies and their Open‐Label Extension

Arthritis &Rheumatology, Accepted Article.
Objectives To evaluate the impact of bimekizumab, a dual IL‐17A and IL‐17F inhibitor, on sacroiliac joint (SIJ) and spine inflammation/structural damage in axSpA using MRIs/radiographs from the phase 3 studies BE MOBILE 1 (nr‐axSpA) and 2 (r‐axSpA) and their open‐label extension (OLE).
Walter P. Maksymowych, Sofia Ramiro, Denis Poddubnyy, Xenofon Baraliakos, Robert G.W. Lambert, Ute Massow, Tom Vaux, Chetan Prajapati, Alexander Marten, Natasha de Peyrecave, Mikkel Østergaard   +10 more
wiley   +1 more source

Baseline Th17/Tc17 and LAG-3 levels serve as candidate exploratory markers for early ixekizumab response in psoriasis

Frontiers in Immunology
IntroductionPsoriasis is a T cell-mediated inflammatory skin disease, and biologics have demonstrated promising efficacy. However, some patients remain dissatisfied with early therapeutic outcomes.
Nan Yang, Nan Yang, Zeyu Chen, Zeyu Chen, Yuxiong Jiang, Yuxiong Jiang, Jiangluyi Cai, Jiangluyi Cai, Lian Cui, Lian Cui, Yuanyuan Wang, Yuanyuan Wang, Suyang Lin, Suyang Lin, Ling Wu, Qian Du, Jun Gu, Jun Gu, Yu Gong, Yu Gong, Qian Yu, Qian Yu, Yuling Shi, Yuling Shi   +23 more
doaj   +1 more source

Review of Pharmacological treatments of Psoriasis

, 2018
This work summarizes the general characteristic of psoriasis in terms of risk factors, epidemiology, clinical presentation, pathophysiology, diagnosis and treatment.hbkáltalános orvosangolegységes ...
Karmon, Idan
core  

Shared and Distinguishing Features of Late‐Onset Rheumatic Diseases Fulfilling Polymyalgia Rheumatica Classification Criteria

Arthritis &Rheumatology, Accepted Article.
‐
Kerem Abacar, Ala Altaie, Andrew Barr, Sarah L. Mackie, Kulveer Mankia, Dennis McGonagle   +5 more
wiley   +1 more source